HBV复制再激活研究进展

李梦苑; 叶传涛; 张颖; 贾战生

doi:10.3969/j.issn.1001-5256.2017.04.036

HBV复制再激活研究进展

DOI: 10.3969/j.issn.1001-5256.2017.04.036

第四军医大学唐都医院传染科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 379
- HTML全文浏览量: 50
- PDF下载量: 145
- 被引次数: 0
出版历程
- 收稿日期: 2016-10-25
- 出版日期: 2017-04-20

Research advances in hepatitis B virus reactivation

Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University

摘要

摘要: 在非活动性或已治愈的HBV感染者中,当机体免疫稳态被打破时,可能发生以肝脏炎症反应和HBV DNA水平增高为表现的HBV再激活(HBVr)现象,进而引起不同程度的肝功能异常、肝衰竭甚至死亡。对于HBVr的筛查、免疫抑制方案的危险分级以及患者个体情况等方面的系统性管理是亟待解决的问题,在免疫抑制治疗及化疗前筛查HBV血清学标志,评估患者HBVr的发生风险,制订合适的个体化预防性抗病毒治疗方案尤为关键。彻底清除肝细胞内ccc DNA是预防HBVr发生的根本。从病因、发病机制、诊断、预防及治疗等方面详细介绍了HBVr的相关研究进展。
- 肝炎病毒,乙型 /
- 病毒激活 /
- 综述
Abstract: In non-active or cured patients with hepatitis B virus ( HBV) infection, when the body's immune homeostasis is broken, HBV reactivation may occur, with the manifestations of liver inflammation and increased HBV DNA level, and lead to varying degrees of abnormal liver function, liver failure, and even death. Systematic management from the aspects of the screening of HBV reactivation, risk stratification of immunosuppression regimens, and patient's individual information needs to be solved urgently. It is very important to perform the screening of HBV serological markers before immunosuppressive therapy and chemotherapy, evaluate the risk of HBV reactivation, and develop individualized prophylactic antiviral therapy. Complete removal of covalently closed circular DNA in hepatocytes is essential for preventing HBV reactivation. This article summarizes related research advances in HBV reactivation from the aspects of its etiology, pathogenesis, diagnosis, prevention, and treatment.
- hepatitis B virus /
- virus activation /
- reviews

HTML全文

参考文献(59)

[1]WHO.Hepatitis B[R/OL].http://www.who.int/mediacemtre/factsheets/fs204/en.html

[2]GANEM D, PRINCE AM.Hepatitis B virus infection-natural history and clinical consequences[J].N Engl J Med, 2004, 350 (11) :1118-1129.

[3]HOOFNAGLE JH.Reactivation of hepatitis B[J].Hepatology, 2009, 49 (Suppl 5) :s156-s165.

[4]PERRILLO RP, GISH R, FALCK-YTTER YT.American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology, 2015, 148 (1) :221-244.

[5]RAN J, FENG P.Recurrence and aggravation of chronic hepatitis B caused by glucocorticoid and immunosuppressant:a clinical analysis of 7 cases[J].West China Med J, 2009, 24 (2) :419-421. (in Chinese) 冉静, 冯萍.糖皮质激素及免疫抑制剂致慢性乙肝复发和加重的7例临床分析[J].华西医学, 2009, 24 (2) :419-421.

[6]YEO W, ZEE B, ZHONG S, et al.Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy[J].Br J Cancer, 2004, 90 (7) :1306-1311.

[7]LAI C, YUEN M.Systemic corticosteroid and reactivation of chronic hepatitis B[J].Respirology, 2010, 15 (7) :1017-1018.

[8]LING WH, SOE PP, PANG AS, et al.Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours[J].Br J Cancer, 2013, 108 (10) :1931-1935.

[9]HSU CH, HSU HC, CHEN HL, et al.Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells.A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy[J].Anticancer Res, 2004, 24 (5A) :3035-3040.

[10]WILCOX RA.Cutaneous B-cell lymphomas:2016 update on diagnosis, risk-stratification, and management[J].Am J Hematol, 2016, 91 (10) :1052-1055.

[11]DONG HJ, NI LN, SHENG GF, et al.Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy:a meta-analysis[J].J Clin Virol, 2013, 57 (3) :209-214.

[12]KIM SJ, HSU C, SONG YQ, et al.Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab:analysis from the Asia Lymphoma Study Group[J].Eur J Cancer, 2013, 49 (16) :3486-3496.

[13]EVENS AM, JOVANOVIC BD, SU YC, et al.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases:meta-analysis and examination of FDA safety reports[J].Ann Oncol, 2011, 22 (5) :1170-1180.

[14]YEO W, CHAN TC, LEUNG NW, et al.Hepatitis B Virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J].J Clin Oncol, 2008, 27 (4) :605-611.

[15]REDDY KR, BEAVERS KL, HAMMOND SP, et al.American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology, 2015, 148 (1) :215-219.

[16]PREZ-ALVAREZ R, DAZ-LAGARES C, GARCA-HERNNDEZ F, et al.Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF) -targeted therapy[J].Medicine, 2011, 90 (6) :359-371.

[17]SHERON N, LAU J, DANIELS H, et al.Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection[J].J Hepatol, 1991, 12 (2) :241-245.

[18]MARINOS G, NAOUMOV NV, ROSSOL S, et al.Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection[J].Gastroenterology, 1995, 108 (5) :1453-1463.

[19]GUIDOTTI LG, CHISARI FV.Noncytolytic control of viral infections by the innate and adaptive immune response[J].Annu Rev Immunol, 2001, 19 (1) :65-91.

[20]HERBEIN G, O'BRIEN WA.Tumor necrosis factor (TNF) -alpha and TNF receptors in viral pathogenesis[J].Proc Soc Exp Biol Med, 2000, 223 (3) :241-257.

[21]GUIDOTTI LG, ISHIKAWA T, HOBBS MV, et al.Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes[J].Immunity, 1996, 4 (1) :25-36.

[22]WEAVER AL.Differentiating the new rheumatoid arthritis biologic therapies[J].J Clin Rheumatol, 2003, 9 (2) :99-114.

[23]CARROLL MB, FORGIONE MA.Use of tumor necrosis factor-αinhibitors in hepatitis B surface antigen-positive patients:a literature review and potential mechanisms of action[J].Clin Rheumatol, 2010, 29 (9) :1021-1029.

[24]AKASHI K, SAEGUSA J, NAKAMACHI Y, et al.Hepatitis B virus reactivation following salazosulfapyridine monotherapy in a patient with rheumatoid arthritis[J].Intern Med, 2016, 55 (10) :1371-1373.

[25]TALOTTA R, ATZENI F, SARZI PUTTINI P.Reactivation of occult hepatitis B virus infection under treatment with abatacept:a case report[J].BMC Pharmacol Toxicol, 2016, 17 (1) :17.

[26]PARK SK, YANG WS, LEE YS, et al.Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine[J].Nephrol Dial Transplant, 2001, 16 (11) :2222-2228.

[27]CHEN GD, GU JL, QIU J, et al.Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers[J].Transpl Infect Dis, 2013, 15 (3) :300-305.

[28]DEHGHANI SM, TAGHAVI SA, GERAMIZADEH B, et al.Hepatitis B recurrence after liver transplantation:a single center experiences and review the literature[J].Hepat Mon, 2013, 13 (1) :e6609.

[29]MIKULSKA M, NICOLINI L, SIGNORI A, et al.Hepatitis B reactivation in HBs Ag-negative/HBc Ab-positive allogeneic haematopoietic stem cell transplant recipients:risk factors and outcome[J].Clin Microbiol Infect, 2014, 20 (10) :694-701.

[30]KOWAZAKI Y, OSAWA Y, IMAMURA J, et al.Immunological analysis of a patient with hepatitis B virus (HBV) reactivation after bone marrow transplantation[J].Intern Med, 2015, 54 (10) :1213-1217.

[31]LIU LG, SHAO YL.Antiviral therapy in patients coinfected with hepatitis B virus and human immunodeficiency virus[J].World Chin J Dig, 2011, 19 (15) :1609-1613. (in Chinese) 柳龙根, 邵幼林.HBV/HIV重叠感染的抗病毒治疗[J].世界华人消化杂志, 2011, 19 (15) :1609-1613.

[32]GMEZ-GONZALO M, CARRETERO M, RULLAS J, et al.The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals:functional roles of NF-kappa B/NF-AT and SP1-binding sites in the HIV-1long terminal repeat promoter[J].J Biol Chem, 2001, 276 (38) :35435-35443.

[33]MU Y, YU Y, YUE X, et al.The X protein of HBV induces HIV-1 long terminal repeat transcription by enhancing the binding of C/EBPβand CREB1/2 regulatory proteins to the long terminal repeat of HIV-1[J].Virus Res, 2011, 156 (1-2) :81-90.

[34]LI YJ, WANG HL, LI TS.Hepatitis B virus/human immunodeficiency virus coinfection:interaction among human immunodeficiency virus infection, chronic hepatitis B virus infection, and host immunity[J].Chin Med J (Engl) , 2012, 125 (13) :2371-2377.

[35]RAIMONDO G, BRUNETTO MR, PONTISSO P, et al.Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients[J].Hepatology, 2006, 43 (1) :100-107.

[36]DONG B, ZHANG PP, ZHAO PD, et al.A case of acute coinfection with HBV and HCV[J].J Clin Hepatol, 2016, 32 (8) :1580-1581. (in Chinese) 东冰, 张萍萍, 赵培东, 等.急性HBV/HCV重叠感染1例报告[J].临床肝胆病杂志, 2016, 32 (8) :1580-1581.

[37]SHIH CM, LO SJ, MIYAMURA T, et al.Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in Hu H-7 cells[J].J Virol, 1993, 67 (10) :5823-5832.

[38]SCHUTTLER CG, FIEDLER N, SCHMIDT K, et al.Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein[J].J Hepatol, 2002, 37 (6) :855-862.

[39]POTTHOFF A, WEDEMEYER H, BOECHER WO, et al.The HEP-NET B/C co-infection trial:a prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection[J].J Hepatol, 2008, 49 (5) :688-694.

[40]LIU PH, RAO HY.Related immune manifestations in patients with chronic hepatitis B virus and chronic hepatitis C virus infection[J].J Clin Hepatol, 2016, 32 (10) :1870-1873. (in Chinese) 刘佩浩, 饶慧瑛.慢性HBV/HCV感染人群伴随的免疫相关表现[J].临床肝胆病杂志, 2016, 32 (10) :1870-1873.

[41]de MONTE A, COURJON J, ANTY R, et al.Direct-acting antiviral treatment in adults infected with hepatitis C virus:reactivation of hepatitis B virus coinfection as a further challenge[J].J Clin Virol, 2016, 78:27-30.

[42]SULKOWSKI MS, CHUANG WL, KAO JH, et al.No evidence of reactivation of hepatitis B virus among patients treated with ledipasvirsofosbuvir for hepatitis C virus infection[J].Clin Infect Dis, 2016, 63 (9) :ciw507.

[43]RAIMONDO G, ALLAIN JP, BRUNETTO MR, et al.Statements from the Taormina expert meeting on occult hepatitis B virus infection[J].J Hepatol, 2008, 49 (4) :652-657.

[44]LOOMBA R, ROWLEY A, WESLEY R, et al.Systematic review:the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy[J].Ann Intern Med, 2008, 148 (7) :519-528.

[45]CHENG AL, HSIUNG CA, SU IJ, et al.Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBVcarriers with lymphoma[J].Hepatology, 2003, 37 (6) :1320-1328.

[46]PERRILLO RP.Acute flares in chronic hepatitis B:the natural and unnatural history of an immunologically mediated liver disease[J].Gastroenterology, 2001, 120 (4) :1009-1022.

[47]YANG PL, ALTHAGE A, CHUNG J, et al.Immune effectors required for hepatitis B virus clearance[J].Proc Natl Acad Sci U S A, 2010, 107 (2) :798-802.

[48]YEO W.Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy[J].J Clin Oncol, 2004, 22 (5) :927-934.

[49]SETO WK, WONG DH, CHAN TY, et al.Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy[J].Am J Gastroenterol, 2016, 111 (12) :1788-1795.

[50]WI CI, LOO NM, LARSON JJ, et al.Low level of hepatitis B virus screening among patients receiving chemotherapy[J].Clin Gastroenterol Hepatol, 2015, 13 (5) :970-975.

[51]TRAN TT, RAKOSKI MO, MARTIN P, et al.Screening for hepatitis B in chemotherapy patients:survey of current oncology practices[J].Aliment Pharmacol Ther, 2010, 31 (2) :240-246.

[52]LEE RS, BELL CM, SINGH JM, et al.Hepatitis B screening before chemotherapy:a survey of practitioners'knowledge, beliefs, and screening practices[J].J Oncol Pract, 2012, 8 (6) :325-328.

[53]DAY FL, LINK E, THURSKY K, et al.Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors:a nationwide survey of medical oncologists[J].J Oncol Pract, 2011, 7 (3) :141-147.

[54]STINE JG, KHOKHAR OS, CHARALAMBOPOULOS J, et al.Rheumatologists'awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy[J].Arthritis Care Res (Hoboken) , 2010, 62 (5) :704-711.

[55]STINE JG, BASS M, IBRAHIM D, et al.Dermatologists awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-αinhibitor therapy[J].South Med J, 2011, 104 (12) :781-788.

[56]NGUYEN GC, SMALLEY WE, VEGE SS, et al.American gastroenterological association institute guideline on the medical management of microscopic colitis[J].Gastroenterology, 2016, 150 (1) :242-246.

[57]ZIAKAS PD, KARSALIAKOS P, MYLONAKIS E.Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma:a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance[J].Haematologica, 2009, 94 (7) :998-1005.

[58]HUANG YH, HSIAO LT, HONG YC, et al.Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B[J].J Clin Oncol, 2013, 31 (22) :2765-2772.

[59]HUANG H, LI X, ZHU J, et al.Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy[J].JAMA, 2014, 312 (23) :2521.

施引文献

资源附件(0)

访问统计